| 000 | 01808 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250515071624.0 | ||
| 264 | 0 | _c20070816 | |
| 008 | 200708s 0 0 eng d | ||
| 022 | _a0340-6245 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aEilertsen, Anette L | |
| 245 | 0 | 0 |
_aDifferential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system. _h[electronic resource] |
| 260 |
_bThrombosis and haemostasis _cJun 2007 |
||
| 300 |
_a938-43 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 |
_aActivated Protein C Resistance _xblood |
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 |
_aBlood Coagulation _xdrug effects |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Combinations |
| 650 | 0 | 4 |
_aEstradiol _xadverse effects |
| 650 | 0 | 4 |
_aEstrogen Receptor Modulators _xadministration & dosage |
| 650 | 0 | 4 |
_aEstrogen Replacement Therapy _xadverse effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNorethindrone _xadverse effects |
| 650 | 0 | 4 | _aNorethindrone Acetate |
| 650 | 0 | 4 |
_aNorpregnenes _xadministration & dosage |
| 650 | 0 | 4 |
_aPostmenopause _xmetabolism |
| 650 | 0 | 4 |
_aProtein C _xmetabolism |
| 650 | 0 | 4 |
_aRaloxifene Hydrochloride _xadministration & dosage |
| 650 | 0 | 4 |
_aSelective Estrogen Receptor Modulators _xadministration & dosage |
| 650 | 0 | 4 | _aTablets |
| 650 | 0 | 4 |
_aThromboembolism _xetiology |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVenous Thrombosis _xetiology |
| 700 | 1 | _aLiestøl, Sigurd | |
| 700 | 1 | _aMowinckel, Marie-Christine | |
| 700 | 1 | _aHemker, H C | |
| 700 | 1 | _aSandset, Per-Morten | |
| 773 | 0 |
_tThrombosis and haemostasis _gvol. 97 _gno. 6 _gp. 938-43 |
|
| 999 |
_c17088550 _d17088550 |
||